WATCH at ₹1,391.80
Recovery is priced in; require supply conversion.
Watch: See corresponding chapter for assumptions and evidence.
Home / Research / Cipla Limited
WATCH at ₹1,391.80
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
Recovery is priced in; require supply conversion.
Watch: See corresponding chapter for assumptions and evidence.
Domestic recurring prescriptions finance the respiratory ramp.
Watch: See corresponding chapter for assumptions and evidence.
Record India sales did not prevent group contraction.
Watch: See corresponding chapter for assumptions and evidence.
Margin/mix residual dominates the earnings decline.
Watch: See corresponding chapter for assumptions and evidence.
SAGE PRO | 16 November 2026 | Q2 FY27 | NSE CIPLA | Reference close ₹1,391.80, 13 November 2026. Consolidated ₹ crore unless stated. WATCH, 6–18 months. Source-verified longform; independent statutory, peer and full institutional QA remain open.
Cipla has two businesses moving in opposite directions. India is setting records while the US franchise is rebuilding its earnings power after a difficult comparison. The investment case is not that a cheap generic company will suddenly become a branded pharmaceutical company. It is that a durable domestic franchise can finance a technically difficult US respiratory platform without forcing shareholders to fund the transition. The price already requires a meaningful recovery. At ₹1,391.80, annualising the quarter's ₹10.86 indicative EPS gives 32.0 times earnings. That is a demanding starting point for a business whose quarterly profit fell 35% year on year. The stock needs both better earnings and confidence that those earnings will survive competition.
Key takeaways
A conventional approval-driven model will bring revenue forward too quickly. A better model stages revenue by usable production, commercial launch, channel inventory and repeat orders. This makes the next two quarters unusually informative: if approved products cannot convert into sales, the investment case weakens even if the regulatory pipeline looks impressive.
The counter-thesis is that India growth and new US launches mask a structural decline in the profitability of mature generics. The previous year's 25% EBITDA margin may not be a reasonable steady-state target.
Our base case therefore does not require a return to 25%. We want to see the company deliver the $250m quarterly North America exit hurdle without a deterioration in cash conversion or a new compliance setback.
A miss on both the revenue hurdle and the full-year margin range would invalidate the near-term recovery thesis. The position belongs on a watchlist rather than being treated as a low-risk compounder at any price.
One India generated ₹3,516 crore, almost 48% of group sales, up 12% year on year. The domestic franchise is built around prescriber relationships, established brands, a large field force and chronic disease treatment. These assets compound through repeated prescriptions rather than one-off product launches. The company reports a 60.3% chronic mix on the IQVIA MAT basis, and its prescription business grew 15% on the YTD September market-data measure. These measures are not interchangeable with reported segment sales. Chronic share is a useful indicator of durability, but the actual cash economics depend on discounts, channel inventories and the cost of acquiring incremental prescriptions.
Key takeaways
Management describes monthly growth of 5–10% for the therapy and strong positioning of Yurpeak. Compounding that rate mechanically for a year would imply 80–214% growth; that is not a forecast. It is a warning against extrapolating early launch curves. A mature model should separate existing chronic prescriptions from new GLP-1 patient cohorts, persistence, pricing and licensing economics.
Trade generics rebounded sequentially but management described year-on-year growth as mid-single digit. That distinction matters: a rebound after disruption is not a new secular growth rate. Consumer health adds a different route to market, with brands such as Nicotex and Omnigel, but advertising and distribution costs determine incremental returns. Neither business should be valued using the same assumptions as a differentiated US inhaler.
North America delivered $172m, up $10m from Q1. The respiratory platform has genuine technical barriers: device design, formulation, manufacturing reproducibility, regulatory equivalence and reliable commercial supply.
Cipla reports 22% share in US albuterol MDI, evidence that it can compete in a mature product. That share is not a direct prediction of Ventolin or Advair share. The new products require separate supply and market-share assumptions.
The US business also faces price erosion and buyer concentration; a complex product is not immune to competition once multiple suppliers enter.
Africa and emerging markets diversify revenue but introduce currency and country risks. One Africa reported $123m and EMEU $101m. South African private-market secondary growth of 6.5% versus 5% market growth is encouraging, but secondary-market growth is not the same as reported group revenue.
Currency translation, tender timing and distribution can move reported results independently. We assign these regions a stabilising role rather than using them to close the US recovery gap.
The India prescription data adds a useful distinction to the growth thesis. The presentation (slides 5–6) reports Foracort above ₹1,000 crore and Dytor above ₹800 crore on the cited market-data basis, with 36 brands exceeding ₹100 crore and 23 brands among the top 300 in the Indian pharmaceutical market. These measures describe brand sales in the market, not necessarily Cipla's booked net revenue, so they must not be summed into the ₹3,516 crore quarterly India figure. They do demonstrate why the domestic platform is less dependent on a single new launch than the US recovery is. In a stress test, if India revenue grows 12% again over its current quarterly base and the remainder of group revenue is unchanged, the incremental ₹422 crore would lift consolidated sales by only 5.7%. If the non-India balance instead contracts by 10%, about ₹389 crore of that increase is erased, leaving growth of roughly 0.4%. This isolates the portfolio arithmetic at constant translation, without forecasting any specific geography. The investment implication is that domestic execution can cushion a weak international portfolio but cannot restore the prior-year group margin on its own. The next disclosure to seek is India growth excluding major recent launches, accompanied by gross contribution and incremental commercial spending, rather than simply brand rankings.
The investor presentation reports Q2 revenue ₹7,404 crore versus ₹7,589 crore, EBITDA ₹1,388 crore versus ₹1,895 crore and PAT ₹878 crore versus ₹1,351 crore. Revenue fell 2.44%, EBITDA 26.75%, and PAT 35.01%. The EBITDA margin fell from 25.0% to 18.7%, a 6.3 percentage-point decline on the rounded presentation basis. The prior-year comparison is the central financial fact; a record India quarter has not yet restored group earnings.
| Metric | Q2 FY26 | Q2 FY27 |
|---|---|---|
| Revenue | 7589 | 7404 |
| EBITDA | 1895 | 1388 |
| PAT | 1351 | 878 |
| EBITDA margin | 25.0% | 18.7% |
Key takeaways
This is why forecasting group sales alone is inadequate. The next recovery must improve contribution economics, not just volume.
Sequentially, the existing display series records Q1 revenue ₹7,119 crore and EBITDA ₹1,192 crore. The quarter improved by ₹285 crore and ₹196 crore respectively, implying an unusually high 69% incremental EBITDA conversion.
This is consistent with a mix and gross-margin recovery, not a sustainable incremental margin assumption. Management reported 64.4% gross margin after material costs and 200bp sequential EBITDA margin expansion.
The display series is not independently statutory-verified; it is corroborative, not a substitute for signed results. Q2 EBITDA excludes other income. The ₹423 crore R&D measure includes depreciation in the deck, so it cannot be deducted again from EBITDA as though it were wholly incremental cash expense.
The balance sheet provides flexibility. Management reports ₹699 crore debt including leases and ₹9,823 crore net cash equivalent at September end. This is a net figure, not gross cash available for distribution.
It implies approximately ₹10,522 crore gross cash-equivalent resources only if the definitions are strictly additive. We do not assume all cash is unrestricted. Net cash is about ₹122 per share using the approximate 80.66 crore share count inferred from the stored market-cap/price pair.
This share count is provisional and not a statutory diluted-share reconciliation.
The quality question is whether the business can turn improved EBITDA into operating cash after inventory builds, receivables, capex and development payments. The new US plant can absorb cash before it reaches efficient utilisation.
A higher reported gross margin alongside rising inventory would not establish durable cash conversion. We have not independently reconciled the half-year cash-flow statement, capital expenditure, restricted cash, working capital or minority attribution.
Accordingly the report does not claim a verified free-cash-flow yield or ROIC. The cash balance is a cushion, not evidence that every future investment earns its cost of capital.
The October 27 call gives an unusually concrete promise: exit FY27 with a $1bn annualised North America revenue rate, equivalent to $250m per quarter. Q2 was $172m, so the gap is $78m, or 45.3%. Q1 was $162m; the latest sequential increase was $10m. A linear continuation of that pace would reach only $192m in Q4. The target requires acceleration, not business as usual.
Key takeaways
Advair is expected to launch in Q3 after approval in Q2; the delay reflects the first DPI product from the new facility. Ventolin's ramp is also supply constrained. This makes plant output and launch timing more useful than an aggregate filing count. The model should not assign all $78m to products that have yet to receive approval.
Lanreotide is specifically excluded from the exit-rate guidance. The company is pursuing remediation at the existing supplier and a new North American site. A return of supply would be upside to the current stated target, not a necessary base-case assumption. Conversely, a failure to restore Lanreotide does not by itself prove that management missed its stated bridge. This distinction prevents double-counting both upside and downside.
Management retained FY27 EBITDA margin guidance of 18.5–20% and R&D guidance of 6–7% of sales. Q2 margin of 18.7% is inside the annual range, but Q1 was weaker. The H2 margin must therefore be assessed on a revenue-weighted basis.
Using Q1 and Q2 display EBITDA of ₹1,192 and ₹1,388 crore and revenue of ₹7,119 and ₹7,404 crore, H1 margin is about 17.76%. If H2 revenue were ₹16,000 crore, H2 EBITDA margin would need to be approximately 19.17% to deliver 18.5% for the year and 22.04% to deliver 20%.
These are analyst arithmetic scenarios, not management forecasts.
The biosimilar programme adds long-term optionality but also development risk. Four programmes are under development and management says their costs are included in R&D. The Qilu pembrolizumab arrangement is a licensing opportunity, not a currently earning asset.
We assign no separately capitalised value to it until commercial terms, launch timing and competition are clearer. Regulatory risk remains tangible: the call reports seven Pithampur Form 483 observations, while a Long Island inspection ended with zero observations.
Neither result should be extrapolated to the entire manufacturing network.
The $250m exit ambition requires more than a single launch: from $172m in Q2, equal compound growth over two quarters would be approximately 20.6% per quarter, taking Q3 to about $207m before reaching $250m in Q4. If Q3 reaches $190m instead, Q4 needs a further 31.6%; at $210m, the remaining increase is 19.0%. These are mathematical checkpoints, not product forecasts. They matter because the transcript indicates multiple launch pathways rather than individual sales commitments. A revenue miss cannot automatically be attributed to a delayed approval: commercial launch, released batches, device yield, distributor stock and reorder behaviour are separate steps. One useful earnings test is a bridge between incremental US revenue and consolidated EBITDA. At an explicitly illustrative exchange rate of ₹90/$, the $78m quarterly gap is ₹702 crore. If fully incremental and converted at a 25–40% contribution margin, it would produce ₹176–281 crore quarterly EBITDA before incremental fixed costs, tax or changes elsewhere. This is only 35–55% of the prior-year EBITDA shortfall of ₹507 crore. Actual currency, pricing and product mix will differ; the exercise shows why the exit-sales milestone alone does not guarantee recovery to the earlier margin. We would insist on evidence of net contribution after launch and manufacturing costs.
We use an illustrative FY28 P/E model rather than a precise DCF because statutory owner cash flows and peer valuation inputs are not independently reconciled. The provisional share count is 80.66 crore, inferred from the existing ₹114,533 crore market cap at ₹1,420. The price reference is the later verified 13 November close of ₹1,391.80. The implied equity value is about ₹112,263 crore. At 28 times earnings, the market requires ₹4,009 crore annual attributable profit, or ₹49.71 EPS. At 24 times, it requires ₹4,678 crore. Q2 PAT annualised is ₹3,512 crore, and this is not a forecast or verified attributable-profit measure.
| FY28 illustration | Bear | Base | Bull |
|---|---|---|---|
| Revenue ₹ crore | 30000 | 34000 | 38000 |
| EBITDA margin | 17% | 21% | 24% |
| EBITDA ₹ crore | 5100 | 7140 | 9120 |
| PAT margin assumption | 10% | 13% | 15% |
| PAT proxy ₹ crore | 3000 | 4420 | 5700 |
| EPS proxy ₹ | 37.19 | 54.80 | 70.67 |
| P/E | 23 | 27 | 31 |
| Value ₹ | 855 | 1480 | 2191 |
Key takeaways
The base offers only about 6% upside before dividends, while the bear implies about 39% downside. This asymmetry explains the watch stance despite the attractive balance sheet. A 20% discount to base value would be roughly ₹1,184, an illustrative margin-of-safety reference rather than a trading instruction.
Sensitivity is transparent: at base revenue, one percentage point of PAT margin changes profit by ₹340 crore, EPS by ₹4.22 and value at 27x by ₹114. A one-turn multiple change moves value by ₹54.80. A 1% increase in share count reduces EPS and value by roughly 1%.
We do not add net cash to a P/E valuation because the earnings multiple already values equity and may include cash income. A separate EV model would require stripping cash interest and reconciling leases and minority interests.
A gross-margin cross-check: 64.4% on ₹7,404 crore implies gross profit of about ₹4,768 crore; subtracting the CFO's ₹3,382 crore expense figure gives roughly ₹1,386 crore, close to reported EBITDA after rounding. This is an indicative bridge, not a statutory reconciliation. At today's revenue, a one-point EBITDA margin increase adds about ₹74 crore quarterly EBITDA.
The next two quarters should be evaluated in sequence. Q3 needs evidence of actual Advair launch and measurable Ventolin supply expansion. A North America revenue level around $200m would represent a useful intermediate analyst checkpoint, not a management commitment. Q4 must approach the stated $250m exit level for the original recovery thesis to hold. If the company reaches the target through a one-time inventory fill, the following quarter's repeat sales and receivables become decisive.
Key takeaways
The financial watchpoint is H2 margin against the revenue-weighted guidance hurdle, with cash conversion and inventory as cross-checks. The regulatory watchpoint is Pithampur remediation and the new US facility's ability to sustain compliant production.
The alternative thesis is that Cipla deserves a higher multiple because the domestic franchise and respiratory barriers create a structurally better business than historical generic earnings suggest. That thesis is plausible but requires evidence of recurring contribution margins after competition arrives.
We would revisit the stance if US revenue approaches the exit target, EBITDA margin moves sustainably above 20%, and statutory operating cash supports the earnings recovery. We would become more cautious if approvals accumulate without shipments or if the annual margin range is cut.
No near-term catalyst should be confused with a permanent increase in intrinsic value.
All scenario inputs are analyst assumptions. Full statutory statement, attributable PAT and diluted shares, cash-flow/capex bridge, peer valuation and independent original-page QA remain outstanding. The report is source-verified research, not full institutional certification.
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
Cipla Q2 FY27 presentation/call or explicitly illustrative valuation model
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.